Public Alert No. 025/2020-Alert on falsified Zinnat Suspension 125mg/5ml circulating in Nigeria
October 27, 2020,
The National Agency for Food and Drug Administration and Control has been informed by GlaxoSmithKline Pharmaceutical Nigeria Limited on the circulation of falsified Zinnat Suspension a brand of Cefuroxime Axetil Lot Number 349R in retail outlets in Nigeria. This lot number (349R) has been used on the genuinely manufactured Zinnat Suspension 125mg/5ml which expired in MAY 2020.
The details of the falsified Zinnat Suspension 125mg/5ml brand of Cefuroxime Axetil is as shown below;
|Product Name||Zinnat Suspension 125mg/5ml|
|Product Manufacturer||Glaxo operations UK Ltd*,
Harmire road, Barnard Castle,
County Durham, United Kingdom.
|Manufacturing date||May. 2019|
|Expiry date||May. 2022|
|Declared Active ingredient||Cefuroxime Axetil 125mg|
- Genuine Zinnat Suspension 125mg /5ml (Cefuroxime Axetil125mg/5ml) Batch Number 349R manufactured by Glaxo operations UK Ltd has Manufacturing date MAY 2018 and Expiry date MAY 2020.
- The genuine Zinnat Suspension 125mg /5ml manufactured by Glaxo operations UK Ltd is registered by NAFDAC with NAFDAC Reg. No: 04-0463.
- Glaxo operations UK Ltd has confirmed that they did not manufacture the affected falsified Zinnat Suspension 125mg /5ml.
Zinnat suspension is indicated for the treatment of the following mild to moderately severe infections caused by sensitive bacteria in paediatric patients 3 months to 12 years; tonsillitis and pharyngitis, acute bacterial otitis media.
NAFDAC implores distributors, retailers and consumers to exercise caution and vigilance to avoid the distribution, sale and use of the falsified Zinnat Suspension 125mg/5ml.
Members of the public in possession of the affected product are implored to discontinue sale or use and submit stock to the nearest NAFDAC office.
Healthcare professionals and consumers are encouraged to report adverse events or side effects related to the use of this product to the nearest NAFDAC office, NAFDAC PRASCOR (20543 TOLL FREE from all networks), via email@example.com or via the NAFDAC ADR e-Reporting platform available at www.nafdac.gov.ng